ロード中...
Inclisiran: First Approval
Inclisiran (Leqvio(®); Novartis) is a first-in-class, cholesterol-lowering small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine carbohydrates (GalNAc). Inclisiran received its first approval in December 2020 in the EU for use in adults with primary hypercholesterolaemia (he...
保存先:
| 出版年: | Drugs |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer International Publishing
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7900795/ https://ncbi.nlm.nih.gov/pubmed/33620677 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-021-01473-6 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|